文献速递外周动脉疾病

药物涂层球囊治疗重症肢体缺血患者股腘病变的IN.PACT Global研究事后分析

Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study.
PubMed 文献 · J Endovasc Ther · 2019-04-01

该事后分析基于IN.PACT Global研究,比较156例重症肢体缺血(CLI)患者与1246例间歇性跛行(IC)患者接受IN.PACT Admiral药物涂层球囊(DCB)治疗股腘病变的1年结局。CLI组病变更长、钙化率更高,12个月免于大截肢率98.6%、免于临床驱动靶病变血运重建(CD-TLR)率86.3%,主要不良事件(MAE)率22.5%,均劣于IC组,但大截肢率仅1.4%,提示DCB在CLI中安全。

要点

  • CLI患者DCB治疗后12个月大截肢率仅1.4%,安全性可接受。
  • CLI组MAE和CD-TLR率高于IC组,再干预更早。
  • CLI组病变较长且钙化率较高,可能影响结局。

核心结论

  • DCB治疗CLI患者股腘病变12个月内安全,大截肢率低(1.4%)。
  • CLI患者MAE和CD-TLR率高于IC患者,再干预更早。

研究设计与样本

  • IN.PACT Global研究的事后分析,纳入1535例受试者,其中156例CLI(Rutherford 4、5级)和1246例IC。
  • CLI组治疗194处股腘病变,IC组治疗1573处病变,随访1年。

主要发现

  • CLI组12个月免于大截肢率为98.6%(95%CI 96.7%~100.0%),IC组为99.9%(95%CI 99.8%~100.0%),p=0.002。
  • CLI组12个月免于CD-TLR率为86.3%(95%CI 80.6%~91.9%),IC组为93.4%(95%CI 91.9%~94.8%),p<0.001。
  • CLI组12个月MAE率为22.5%,IC组为10.7%,p<0.001。
  • CLI组总生存率为93.0%(95%CI 88.9%~97.2%),IC组为97.0%(95%CI 96.0%~97.9%),p=0.011。
  • CLI组病变长度13.9±10.6 cm,IC组11.9±9.4 cm,p=0.009;CLI组钙化率76.8%,IC组67.7%,p=0.011。

临床怎么用

  • DCB可用于CLI患者股腘病变,但需预期MAE和CD-TLR风险较高且再干预更早。
  • CLI患者病变较长且钙化率高,治疗策略需考虑这些特征。

局限性

  • 为事后分析,非预设主要终点。
  • CLI样本量较小(156例),需进一步研究长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report a post hoc analysis performed to evaluate 1-year safety and efficacy of the IN.PACT Admiral drug-coated balloon (DCB) for the treatment of femoropopliteal lesions in subjects with critical limb ischemia (CLI) enrolled in the IN.PACT Global study ( ClinicalTrials.gov identifier NCT01609296). MATERIALS AND METHODS: Of 1535 subjects enrolled in the study, 156 participants (mean age 71.8±10.4; 87 men) with CLI (Rutherford categories 4,5) were treated with DCB angioplasty in 194 femoropopliteal lesions. This cohort was compared to the 1246 subjects (mean age 68.2±10.0 years; 864 men) with intermittent claudication (IC) treated for 1573 lesions. The CLI cohort had longer lesions (13.9±10.6 vs 11.9±9.4 cm, p=0.009) and a higher calcification rate (76.8% vs 67.7%, p=0.011). Major adverse events [MAE; composite of all-cause mortality, clinically-driven target lesion revascularization (CD-TLR), major (above-ankle) target limb amputation, and thrombosis at the target lesion site], lesion and vessel revascularization rates, and EuroQol-5D were assessed through 1 year. The Kaplan-Meier method was used to estimate survival, CD-TLR, and amputation events; estimates are presented with the 95% confidence intervals (CI). RESULTS: Estimates of 12-month freedom from major target limb amputation were 98.6% (95% CI 96.7% to 100.0%) in subjects with CLI and 99.9% (95% CI 99.8% to 100.0%) in subjects with IC (p=0.002). Freedom from CD-TLR through 12 months was 86.3% (95% CI 80.6% to 91.9%) in CLI subjects and 93.4% (95% CI 91.9% to 94.8%) in IC subjects (p<0.001). The MAE rate through 12 months was higher in CLI subjects (22.5% vs 10.7%, p<0.001), and CLI patients had poorer overall survival (93.0%, 95% CI 88.9% to 97.2%) than IC subjects (97.0%, 95% CI 96.0% to 97.9%, p=0.011). Health status significantly improved in all domains at 6 and 12 months in both groups. CONCLUSION: Treatment of femoropopliteal disease with DCB in CLI patients is safe through 12-month follow-up, with a low major amputation rate of 1.4%. The rates of MAE and CD-TLR were higher in CLI subjects and reinterventions were required sooner. Additional research is needed to evaluate long-term outcomes of DCB treatment for femoropopliteal lesions in CLI patients.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Reijnen MMPJ, van Wijck I, Zeller T, et al. Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study. J Endovasc Ther. 2019. PMID: 30931726. doi:10.1177/1526602819839044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。